Turning conversation into lasting intelligence
PRISME Forum Field Notes capture selected signals, tensions, emerging practices and unresolved questions surfaced through member meetings and related exchanges.
They are not meeting minutes, formal industry positions or prescriptions for what companies should do. They are concise records of what senior R&D technology leaders are seeing, questioning and working through together.
AI Adoption in R&D: from Pilots to Operating Model Reality
As AI moves deeper into biopharma R&D, the questions are shifting.
The conversation is no longer only about whether a model or tool works. Increasingly, R&D technology leaders are asking what happens when AI becomes part of the operating environment: who owns it, how it is governed, whether the underlying data can be trusted, how human and AI-enabled work should interact, and what durable adoption looks like beyond the pilot stage.
The Brussels discussions surfaced a broader transition from technology experimentation toward operating-model design.
Among the questions emerging:
- What makes an AI-enabled workflow truly operational rather than experimental?
- Who owns and governs AI once it moves into day-to-day R&D work?
- How should human expertise and AI agents work together?
- What data foundations are required for trusted AI-enabled decisions?
- How can experimentation be encouraged without creating fragmented technology, data or accountability?
- How should R&D technology leaders think about the long-term cost and operating implications of AI at scale?
Full PRISME Forum Field Notes are available to members.
Members: read the Field Notes →Inside the member knowledge base
Public Insights show selected themes and questions emerging from the community. The fuller record remains available only within the protected member environment.
Across its history, PRISME Forum has compiled more than 700 meeting documents and resources, individually organized, labeled and tagged to help members locate relevant presentations, past discussions and accumulated Forum experience.
PRISME Forum periodically conducts confidential benchmarking, surveys and targeted member inquiries across selected R&D technology topics, allowing members to compare approaches, priorities and operating experience while protecting company-specific and commercially sensitive information.
This includes PRISME Forum’s biennial R&D financial and digital benchmarking, alongside targeted surveys and member inquiries addressing emerging priorities.
Questions shaping R&D technology leadership
The remit of R&D technology continues to expand well beyond traditional IT.
PRISME Forum discussions increasingly span digital R&D, data and informatics, AI, scientific computing, technology architecture, automation, clinical development technology and the operating models needed to support them.
How do organizations move promising technologies from experimentation into workflows that produce durable R&D value?
How should R&D organizations strengthen the data, architecture and accountability needed to support increasingly AI-enabled scientific work?
Which capabilities remain human-led, which become AI-assisted, and how should roles, skills and organizational structures evolve?
How can organizations create enough control to manage risk while preserving the freedom to experiment and innovate?
As technology choices multiply, how should R&D leaders decide what to build, what to buy, what to embed and what to retire?
Member intelligence
PRISME Forum membership is selective and subject to the Forum’s eligibility criteria. Senior leaders whose responsibilities span digital, data, technology and related capabilities across biopharma R&D are welcome to inquire about whether the Forum may be a fit.